Long-acting injectable cabotegravir (CAB LA)

news

European Commission approves long-acting HIV drug option

19 September 2023 | By Catherine Eckford (European Pharmaceutical Review)

The first long-acting injectable PrEP option proven superior to daily oral FTC/TDF in reducing HIV acquisition, has been approved in the European Union (EU).

news

Generic manufacturers sign sublicences to produce long-acting HIV medicine

31 March 2023 | By Catherine Eckford (European Pharmaceutical Review)

Sublicence agreements signed by the Medicines Patent Pool (MPP) and three generic manufacturers could enable millions to access a long-acting HIV medicine.

news

ViiV agrees to expand access to long-acting HIV PrEP

1 August 2022 | By Hannah Balfour (European Pharmaceutical Review)

Under a new agreement, licenced manufacturers will be able to supply generic versions of ViiV’s long-acting cabotegravir HIV pre-exposure prophylaxis (PrEP) medication to developing nations.

news

Altruistic initiatives aim to improve patient care in developing regions

7 June 2022 | By Mandy Parrett (European Pharmaceutical Review)

Ambitions to reach greater numbers of patients with unmet need have fuelled some benevolent plans from bio/pharmaceutical companies ViiV Healthcare and Sandoz.

news

Trial of new HIV PrEP medication stopped early due to effectiveness

10 November 2020 | By Hannah Balfour (European Pharmaceutical Review)

The trial was stopped because the data suggested that injections of the long-acting antiretroviral drug cabotegravir (CAB LA) are highly effective for HIV pre-exposure prophylaxis (PrEP) in women.